Stock P2OD34 INSULET CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Insulet Corporation Sao Paulo

Equities

P2OD34

BRP2ODBDR009

Medical Equipment, Supplies & Distribution

Market Closed - Sao Paulo
Other stock markets
 12:54:31 2024-06-24 pm EDT 		5-day change 1st Jan Change
36.66 BRL +14.35% Intraday chart for Insulet Corporation +14.35% -24.41%
Jun. 24 Transcript : Insulet Corporation - Special Call
Jun. 22 Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,584 16,853 18,350 20,445 15,151 14,134 - -
Enterprise Value (EV) 1 11,096 16,949 18,807 21,172 15,863 14,571 14,288 13,941
P/E ratio 901 x 2,556 x 1,109 x 4,206 x 73.8 x 65.5 x 53.4 x 42.1 x
Yield - - - - - - - -
Capitalization / Revenue 14.3 x 18.6 x 16.7 x 15.7 x 8.93 x 7.14 x 6.03 x 5.16 x
EV / Revenue 15 x 18.7 x 17.1 x 16.2 x 9.35 x 7.36 x 6.1 x 5.09 x
EV / EBITDA 142 x 139 x 103 x 94.2 x 48.2 x 35.8 x 28.7 x 22.9 x
EV / FCF -170 x -377 x -104 x -5,429 x 226 x 51.8 x 46.6 x 36.6 x
FCF Yield -0.59% -0.27% -0.96% -0.02% 0.44% 1.93% 2.14% 2.73%
Price to Book 141 x 28 x 33.1 x 43 x 21.8 x 14.2 x 9.93 x 7.62 x
Nbr of stocks (in thousands) 61,822 65,928 68,967 69,449 69,828 70,040 - -
Reference price 2 171.2 255.6 266.1 294.4 217.0 201.8 201.8 201.8
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 738.2 904.4 1,099 1,305 1,697 1,980 2,343 2,740
EBITDA 1 77.9 121.5 183.4 224.8 329.2 407.2 497.9 609.4
EBIT 1 50 66.1 126 124.1 208.5 267.5 342.9 439.7
Operating Margin 6.77% 7.31% 11.47% 9.51% 12.29% 13.51% 14.63% 16.05%
Earnings before Tax (EBT) 1 14.5 9.7 20.5 9.8 214.6 260.8 337.9 435.5
Net income 1 11.6 6.8 16.8 4.6 206.3 228.6 282.5 357.7
Net margin 1.57% 0.75% 1.53% 0.35% 12.16% 11.54% 12.05% 13.05%
EPS 2 0.1900 0.1000 0.2400 0.0700 2.940 3.082 3.776 4.796
Free Cash Flow 1 -65.3 -45 -180 -3.9 70.1 281.2 306.3 381.1
FCF margin -8.85% -4.98% -16.38% -0.3% 4.13% 14.2% 13.07% 13.91%
FCF Conversion (EBITDA) - - - - 21.29% 69.06% 61.52% 62.55%
FCF Conversion (Net income) - - - - 33.98% 123.06% 108.45% 106.57%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 307.7 295.4 299.4 340.8 369.7 358.1 396.5 432.7 509.8 441.7 460.2 506 571.2 534.7 555.3
EBITDA 1 64.6 63 27.6 62.8 71.4 48.8 61.3 82.8 137 89.2 82.08 97.62 128.1 129.1 110.5
EBIT 1 49.7 37.9 -26.7 2.9 42.5 19.7 30.3 52.9 105.5 56.9 49.59 66.32 94.6 68.61 75.14
Operating Margin 16.15% 12.83% -8.92% 0.85% 11.5% 5.5% 7.64% 12.23% 20.69% 12.88% 10.78% 13.11% 16.56% 12.83% 13.53%
Earnings before Tax (EBT) 1 33.4 29.3 -36.1 -5.7 22.3 24.6 28.5 53.7 107.8 54.9 52.4 63.93 90.57 67.1 73.86
Net income 1 29.2 27.8 -35 -5.2 17 23.8 27.3 51.9 103.3 51.5 43.48 55.2 78.2 59.24 64.34
Net margin 9.49% 9.41% -11.69% -1.53% 4.6% 6.65% 6.89% 11.99% 20.26% 11.66% 9.45% 10.91% 13.69% 11.08% 11.59%
EPS 2 0.4200 0.4000 -0.5000 -0.0800 0.2400 0.3400 0.3900 0.7400 1.440 0.7300 0.5756 0.7720 1.069 0.7522 0.8089
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/23/22 5/5/22 8/4/22 11/3/22 2/23/23 5/4/23 8/8/23 11/2/23 2/22/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 512 96.1 457 727 712 437 154 -
Net Cash position 1 - - - - - - - 193
Leverage (Debt/EBITDA) 6.57 x 0.7909 x 2.493 x 3.234 x 2.162 x 1.074 x 0.309 x -
Free Cash Flow 1 -65.3 -45 -180 -3.9 70.1 281 306 381
ROE (net income / shareholders' equity) 12.9% 5.01% 2.9% 17.6% 34.1% 25.1% 21.1% 20.1%
ROA (Net income/ Total Assets) 1.12% 1.13% 0.86% 4.24% 8.53% 7.71% 8.25% 9.03%
Assets 1 1,036 601.9 1,960 108.6 2,420 2,965 3,423 3,960
Book Value Per Share 2 1.210 9.140 8.040 6.850 9.950 14.20 20.30 26.50
Cash Flow per Share 2 1.580 1.270 -0.9900 1.700 1.980 3.320 3.930 4.780
Capex 1 164 129 112 123 75.6 138 125 129
Capex / Sales 22.18% 14.26% 10.18% 9.42% 4.45% 6.96% 5.32% 4.7%
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Insulet Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
201.8 USD
Average target price
233.6 USD
Spread / Average Target
+15.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.60% 181B
MEDTRONIC PLC Stock Medtronic plc
-4.45% 101B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.15% 67.54B
DEXCOM, INC. Stock DexCom, Inc.
-8.63% 45.09B
CENCORA, INC. Stock Cencora, Inc.
+9.70% 44.37B
HOYA CORPORATION Stock Hoya Corporation
+6.13% 40.7B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.22% 29.85B
TERUMO CORPORATION Stock Terumo Corporation
+14.80% 24.49B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.46% 23.99B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. PODD Stock
  4. P2OD34 Stock
  5. Financials Insulet Corporation